Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bullishMedium impact
Esc

Moderna Stock Surges 9% on mRNA Cancer Vaccine Phase 3 Win

Yahoo Finance2 min read6 sources

Why is Moderna stock up today?

Moderna (MRNA) stock surged 9% on Friday, lifted to $149 by a personalized mRNA cancer vaccine Phase 3 win with Merck, two recent FDA approvals, and pre-conference investor positioning.

Key numbers

MRNA 1-day gain+8.6%Intraday high $149.26 on Sept 11, 2026
MRNA YTD 2026~404%From ~$29 at Jan 1 open
INTerpath-001 Phase 3 patients1,137Met primary RFS and secondary DMFS endpoints vs Keytruda alone
mFLUSIVA vs standard flu shot+27% efficacyIn adults 50+; FDA approved Aug 5, 2026
2026 revenue guidance~$2.1BUp to +10% over 2025 revenue of ~$1.9B (per Q2 2026 8-K)
Cash on hand$6.9BAs of June 30, 2026

What happened

Moderna (MRNA) stock surged 9% on Friday, lifted to $149 by a personalized mRNA cancer vaccine Phase 3 win with Merck, two recent FDA approvals, and pre-conference investor positioning. In August, Moderna and Merck revealed that their personalized cancer vaccine — intismeran autogene (mRNA-4157) — significantly reduced melanoma recurrence risk in a 1,137-patient Phase 3 trial, beating the cancer drug Keytruda used alone. The FDA cleared mFLUSIVA, the first mRNA flu vaccine approved in the United States, on August 5, then approved updated COVID-19 vaccines on August 27. Investors are positioning ahead of Moderna's presentation at the Morgan Stanley Global Healthcare Conference on September 14.

Why it matters

Moderna stock has become one of 2026's most dramatic turnaround stories, rising from about $29 at the start of the year to nearly $150 — and the cancer vaccine trial is the main reason why. A personalized cancer vaccine custom-built from each patient's own tumor mutations would be the first of its kind to reach patients, opening a potential new era in cancer treatment worth billions annually. The FDA approvals of mFLUSIVA and the updated COVID shot prove Moderna can win regulatory battles well beyond its original COVID business.

Who this affects

Marketbullish
Medium impact
Pharma stocks gain as mRNA platform confidence rises.
Companybullish
High impact
Shareholders benefit as Moderna diversifies beyond COVID revenue.
Competitorsbearish
Medium impact
BioNTech faces stiffer mRNA cancer competition from Moderna.
Industrybullish
High impact
mRNA validated for cancer and flu treatment beyond COVID.

Moderna vs BioNTech, Pfizer, Merck

ModernaMRNA$57B+8.6%~404%N/A
BioNTechBNTX$24B+0.3%~flatN/A
PfizerPFE$158B+0.3%+14%~10x
MerckMRK$355B-0.5%+44%~17x

As of 2026-09-11

How we got here

  1. FDA approves mFLUSIVA — first mRNA flu vaccine cleared in the U.S.

  2. Merck-Moderna Phase 3 cancer vaccine beats Keytruda alone; MRNA surges ~145%

  3. FDA clears updated Spikevax and mNEXSPIKE COVID-19 vaccines for 2026-2027

  4. Argus Research upgrades MRNA to Buy, sets $180 price target

  5. MRNA surges 9% on momentum and pre-conference positioning; no new day-of catalyst

What to watch

  • Morgan Stanley conference Sept 14 — management may update pipeline and guidance.2026-09-14
  • ESMO Congress Oct 23-27 — full Phase 3 intismeran hazard-ratio data expected.2026-10-23
  • BLA regulatory filing timeline for intismeran autogene with FDA to be confirmed.2026 H2

Educational content only. Not investment advice.

More briefsAll briefs →